FGFR3 and central nervous system cancer: In FGFR3-TACC3 fusion-positive glioma cell lines, the FGFR-inhibitors PD173074 and AZD4547 had an antiproliferative effect, and the kinase inhibitor pazopanib caused cell cycle arrest [40].